• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [25557 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     Agency for Care Effectiveness (ACE) Positive airway pressure for moderate-to-severe obstructive sleep apnoea
2026     Agency for Care Effectiveness (ACE) Biologics for treating atopic dermatitis
2026     Agency for Care Effectiveness (ACE) Icatibant and sebetralstat for treating hereditary angioedema attacks
2026     Agency for Care Effectiveness (ACE) Equecabtagene autoleucel for relapsed or refractory multiple myeloma
2026     Agency for Care Effectiveness (ACE) Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer
2026     Agency for Care Effectiveness (ACE) RSVpreF maternal vaccine for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants
2026     Agency for Care Effectiveness (ACE) Clesrovimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season
2026     Agency for Care Effectiveness (ACE) Brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
2026     Agency for Care Effectiveness (ACE) Osimertinib for maintenance treatment of locally advanced, unresectable EGFR mutation-positive non-small-cell lung cancer during or following chemoradiation therapy
2026     Agency for Care Effectiveness (ACE) Nivolumab and relatlimab for first-line treatment of unresectable or metastatic melanoma
2026     Agency for Care Effectiveness (ACE) Durvalumab for treating resectable gastric or gastroesophageal junction adenocarcinoma
2026     Agency for Care Effectiveness (ACE) Belzutifan for von Hippel-Lindau disease with associated non-metastatic renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumours
2026     Agency for Care Effectiveness (ACE) Biologics as add-on therapy for treating chronic rhinosinusitis with nasal polyps
2026     Agency for Care Effectiveness (ACE) Elacestrant for ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation
2026     Agency for Care Effectiveness (ACE) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant
2026     Agency for Care Effectiveness (ACE) Nirsevimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season
2026     Agency for Care Effectiveness (ACE) Maribavir for treating refractory or drug-intolerant cytomegalovirus infection after transplant
2026     Agency for Care Effectiveness (ACE) Vutrisiran for transthyretin amyloid cardiomyopathy
2026     Andalusian Health Technology Assessment Area (AETSA) [Systems for the estimation of coronary flow and myocardial perfusion through angiographic analysis software]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Chronic obstructive pulmonary disease: performing diagnostic pre-/postbronchodilator spirometry and interpreting the results]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Multiple sclerosis in the era of the new McDonald criteria]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Living environments for seniors experiencing a loss of independence]
2026     Austrian Institute for Health Technology Assessment (AIHTA) Effectiveness of health warning labels on alcoholic beverages: a systematic review with a narrative analysis for Austria
2026     Austrian Institute for Health Technology Assessment (AIHTA) Oncology pipeline monitor 2026: pilot approach of using IHSI data to inform hospital decision-makers in Austria on emerging medicinal products
2026     Austrian Institute for Health Technology Assessment (AIHTA) Amivantamab plus lazertinib vs osimertinib plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer
2026     Austrian Institute for Health Technology Assessment (AIHTA) Assessment of interventions addressing social media use among children and adolescents
2026     Health Sciences Institute in Aragon (IACS) [Criteria for designing primary care training programs on mental health and suicide prevention in children and adolescents]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Latent infection screening before initiating immunosuppressive cancer treatment]
2026     National Institute for Health and Care Excellence (NICE) Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment. NICE HealthTech guidance 781
2026     National Institute for Health and Care Excellence (NICE) Nemolizumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 1191
2026     National Institute for Health and Care Excellence (NICE) Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer. NICE technology appraisal guidance 1190
2026     National Institute for Health and Care Excellence (NICE) Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years. NICE technology appraisal guidance 1192
2026     National Institute for Health and Care Excellence (NICE) Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable. NICE technology appraisal guidance 1193
2026     National Institute for Health and Care Excellence (NICE) Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 1194
2026     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable. NICE technology appraisal guidance 1195
2026     HTA Region Stockholm [Consequences of replacing chest x-ray with ultra-low-dose computed tomography in patients with a low suspicion of lung cancer]
2026     HTA South [Camera-based autofluorescence during total thyroidectomy]
2026     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) AIRe – multidisciplinary rehabilitation platform
2026     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) BitHabit® – application for lifestyle guidance and mental wellbeing
2026     Basque Office for Health Technology Assessment (OSTEBA) [Telemonitoring and computerised management of patients receiving home dialysis and rehabilitation]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Detection of dihydropyrimidine dehydrogenase deficiency prior to fluoropyrimidine-based chemotherapy]
2026     Canada’s Drug Agency (CDA-AMC) Teleoptometry for eye exams
2026     Canada’s Drug Agency (CDA-AMC) Antiviral drugs for the treatment of suspected or confirmed influenza A or influenza B
2026     Canada’s Drug Agency (CDA-AMC) Cryoneurolysis for patients undergoing total knee arthroplasty
2026     Canada’s Drug Agency (CDA-AMC) Cryoneurolysis for patients undergoing surgical stabilization of rib fractures
2026     Canada’s Drug Agency (CDA-AMC) Dosing of immune checkpoint inhibitors
2026     Canada’s Drug Agency (CDA-AMC) Nabilone for the management of behavioral and psychological symptoms of dementia
2026     Canada’s Drug Agency (CDA-AMC) Teleaudiology for hearing assessments
2026     Canada’s Drug Agency (CDA-AMC) Longevity of relined or rebased dentures
2026     Canada’s Drug Agency (CDA-AMC) Dextrose prolotherapy for musculoskeletal conditions
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Hypertension – antihypertensive medication adjustment and monitoring]
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Tirzepatide (Zepbound)]
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Donanemab (Kisunla)]
2026     Basque Office for Health Technology Assessment (OSTEBA) [Home self-management of oral anticoagulation therapy with vitamin K antagonists: evaluation of acceptability and cost-effectiveness]
2026     Basque Office for Health Technology Assessment (OSTEBA) [Active piezoelectric bone conduction hearing implant]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Single-port endoluminal robotic system for endoscopic submucosal dissection in patients with superficial colorectal lesions]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to the management of advanced neuroendocrine tumors]
2026     Canada’s Drug Agency (CDA-AMC) Ferric derisomaltose for heart failure and iron deficiency
2026     Canada’s Drug Agency (CDA-AMC) Botulinum toxin A product comparison for upper limb spasticity, lower limb spasticity, and cervical dystonia
2026     Canada’s Drug Agency (CDA-AMC) Cost-effectiveness of antiviral drugs to prevent or treat influenza A, influenza B, or zoonotic influenza
2026     Canada’s Drug Agency (CDA-AMC) Antiviral drugs for post-exposure prophylaxis against influenza A or influenza B
2026     Scottish Health Technologies Group (SHTG) National framework for evaluating the role of Surgical Care Practitioners (SCPs) in Scotland
2026     Scottish Health Technologies Group (SHTG) Pre-hospital extracorporeal cardiopulmonary resuscitation (ECPR) for adult patients experiencing refractory out-of-hospital cardiac arrest (OHCA)
2026     Scottish Health Technologies Group (SHTG) Computed tomography coronary angiography (CTCA) and CT fractional flow reserve (CT-FFR) for investigation of patients with stable chest pain
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital self-care solutions for non-specific lower back pain]
2026     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Benefits and risks of using smart infusion pumps for parenteral drug administration]
2026     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Bioimpedance phase angle analysis as prognostic in patients with palliative care needs in chronic non-oncological diseases]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Comparison of the Edgington method with standard procedures for fixed-effect meta-analyses in a scenario with 2 studies]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Thresholds for responder analyses of complex scales in benefit assessments – the 15% approach]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Second addendum to Project A26-11]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inotuzumab ozogamicin (relapsed/refractory ALL, children >= 1 year ) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pretomanid (tuberculosis) – Assessment according to §35a (para. 1c) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tovorafenib (low-grade glioma in paediatric patients) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belumosudil (chronic graft-versus-host disease in adults and children 12 years and older) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; adjuvant treatment) –Addendum to Project A26-17]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction) – Addendum to Project A26-16]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (acute myeloid leukaemia) – Addendum to Project A26-19]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clesrovimab (secondary prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deucravacitinib (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab/relatlimab (melanoma) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aficamten (obstructive hypertrophic cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clascoterone (acne vulgaris) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, newly diagnosed, consolidation therapy) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, 1st and 2nd complete remission) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, refractory or relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, relapsed or refractory) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia B, with factor IX inhibitors) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia A, with factor VIII inhibitors) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (CML, T315I mutation, previously treated) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zolbetuximab (gastric or gastro-oesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (chronic spontaneous urticaria in adults and adolescents 12 years and above) – Benefit assessment according to §35a]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (chronic spontaneous urticaria in children >= 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olipudase alfa (acid sphingomyelinase deficiency) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Cell and gene therapies: reflections for optimal deployment]
2026     National Institute for Health and Care Excellence (NICE) Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation. NICE HealthTech guidance 780
2026     National Institute for Health and Care Excellence (NICE) Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 1182
2026     National Institute for Health and Care Excellence (NICE) Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 1185